News & Events

Date Title and Summary Additional Formats
Toggle Summary Vertex Pharmaceuticals Announces Two Senior Management Changes
Vertex Pharmaceuticals Announces Two Senior Management Changes Cambridge, MA, February 8, 2005 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that Dr. Vicki Sato will retire as President of the Company effective during the second quarter of 2005. Dr.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference Cambridge, MA, February 3, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Merrill Lynch's
View HTML
Toggle Summary Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast
Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast Cambridge, MA, February 2, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its fourth quarter and full year 2004 financial results on Wednesday,
View HTML
Toggle Summary Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference
Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 10, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today will review its 2004 achievements and will describe its 2005
View HTML
Toggle Summary Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Whitehouse Station, NJ and Cambridge, MA, January 6, 2005 -- Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have begun a Phase I
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at JPMorgan's 23rd Annual Healthcare Conference in San
View HTML
Toggle Summary Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART
Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART Montego Bay, Jamaica, December 15, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) plus ritonavir (LEXIVA/r) dosed once daily (QD)
View HTML
Toggle Summary Novartis Selects Drug Candidate for Clinical Development from Protein Kinase Research Collaboration with Vertex
--Novel compound, VX-322, targets key mechanisms implicated in leukemia and other cancers--
View HTML
Toggle Summary Vertex Pharmaceuticals Receives Distinguished Recognition by Scientific American Magazine
- Company named Business Leader in Medical Treatment in the 2004 "Scientific American 50" -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
-- First study in HCV patients will evaluate dosing up to 14 days --
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
-Encouraging Results Support Initiation of Phase Ib Clinical Study-
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update
Company continues to achieve its financial and pipeline goals
View HTML
Toggle Summary Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients
-First demonstration of CRP reduction in cardiovascular patients using an oral cytokine inhibitor-
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C
Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, September 7, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has successfully completed the
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update
--Company on Track to Achieve 2004 Milestones--
View HTML
Toggle Summary GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV
GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV London, UK, July 16, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received marketing approval from the
View HTML
Toggle Summary Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC
Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC Bangkok, July 13, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium, formerly GW433908, or 908) in combination with abacavir and lamivudine demonstrated sustained efficacy and safety
View HTML
Toggle Summary Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC
Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC Bangkok, July 12, 2004 -- HIV treatment regimens containing the protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir
View HTML
Toggle Summary 48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS
48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS Research Triangle Park, NC, July 8, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) once-daily (QD) as part of a
View HTML
Toggle Summary Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer
Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Whitehouse Station, NJ and Cambridge, MA, June 22, 2004 -- Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today
View HTML
Toggle Summary Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries
Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries Cambridge, MA, June 14, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that Vertex and Mitsubishi
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Discovery of Two New Classes of Compounds Targeting Cystic Fibrosis
Research Results Presented at CF Foundation's Williamsburg Conference
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, June 8, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the initiation of a Phase I clinical
HCV
View HTML
Toggle Summary Cystic Fibrosis Foundation Therapeutics Awards $21 Million to Vertex Pharmaceuticals Under Expanded Agreement
- New Collaboration Builds on Drug Discovery Progress at Vertex -
View HTML
Toggle Summary Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting
Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting Cambridge, MA, May 6, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today results of the voting at its 2004 Annual Meeting of Shareholders.
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV
Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV Tucson, AZ, May 4, 2004 -- New preclinical data for two proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex Pharmaceuticals
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress
Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress Cambridge, MA, April 26, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2004.
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches
Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches Berlin, Germany, April 16, 2004 -- New data for proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex
HCV
View HTML
Toggle Summary GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R)
GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R) Cambridge, MA, March 25, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received a positive opinion from the European Committee for Proprietary
View HTML
Toggle Summary Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Tumor Regression In Vivo with Aurora Kinase Inhibitors
- Study Published in Nature Medicine -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange
Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange Cambridge, MA, February 13, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has completed the exchange of approximately $153 million in aggregate principal amount of its 5% Convertible
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004
Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004 Cambridge, MA, February 11, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the year ended December 31, 2003.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007
Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007 Cambridge, MA, February 10, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that five holders of its existing 5% Convertible
View HTML
Toggle Summary Vertex and Novartis Amend Drug Discovery and Development Collaboration
Vertex and Novartis Amend Drug Discovery and Development Collaboration Cambridge, MA, February 3, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex and Novartis Pharma AG have amended their collaboration directed at targets in the protein kinase gene family.
View HTML
Toggle Summary Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
-Company to Provide Financial Guidance for 2004-
View HTML
Toggle Summary Vertex Researchers Publish Structure of FLT-3 Kinase in Molecular Cell
-Potential Mechanism Underlying Various Types of Leukemia Described-
View HTML
Toggle Summary Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS)
Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS) Cambridge, MA and Research Triangle Park, NC, January 20, 2004 -- The final 48-week results from the NEAT trial, an open-label, multi-center study
View HTML
Toggle Summary Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference
Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference Cambridge, MA, January 12, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented its 2003 accomplishments and 2004 outlook at the 22nd Annual JPMorgan
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results
Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results Cambridge, MA, October 24, 2001 — Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reported consolidated financial results today for the three and nine months ended September 30, 2001.
View HTML